Evidence map›Paper›PMID 31908556›Full record

ArticleLung Cancer (Auckland, N.Z.)2019

Outcomes Following Stereotactic Body Radiotherapy with Intensity-Modulated Therapy versus Three-Dimensional Conformal Radiotherapy in Early Stage Non-Small Cell Lung Cancer.

Michael Mix, Sean Tanny, Tamara Nsouli, Ryan Alden, Rishabh Chaudhari, Russell Kincaid, Paula F Rosenbaum, Jeffrey A Bogart, Paul Aridgides

Open access · goldAbstract read
In one paragraph

Article in Lung Cancer (Auckland, N.Z.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Michael MixDepartment of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY 13210, USA.
Sean TannyDepartment of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY 13210, USA.ORCID 0000-0002-0915-9187
Tamara NsouliDepartment of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY 13210, USA.
Ryan AldenDepartment of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY 13210, USA.ORCID 0000-0003-4040-1864
Rishabh ChaudhariDepartment of Radiation Oncology, University of Cincinnati/University Hospital Barrett Cancer Center, Cincinatti, OH 45267, USA.ORCID 0000-0001-7230-5813
Russell KincaidDepartment of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY 13210, USA.
Paula F RosenbaumDepartment of Public Health and Preventive Medicine, SUNY Upstate Medical University, Syracuse, NY, 13210, USA.
Jeffrey A BogartDepartment of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY 13210, USA.ORCID 0000-0001-5657-6613
Paul AridgidesDepartment of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY 13210, USA.ORCID 0000-0001-6249-7399
SUNY Upstate Medical University · USUniversity of Cincinnati · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe treatment techniques used for stereotactic body radiation therapy (SBRT) for early-stage lung cancer continue to evolve. In this study, clinical outcomes following SBRT were evaluated according to the use of either 3D conformal radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT). PATIENTS AND

methodsPatients with stage I NSCLC who received SBRT from 2007 to 2015 were retrospectively reviewed. Disease control and survival were assessed using Kaplan-Meier estimates. Dosimetric analyses for target dose heterogeneity and coverage were performed.

resultsA total of 297 patients with 351 lesions were included. 3DCRT was used in 52% and IMRT in 48%. IMRT was utilized at a higher rate in more recent years. The most common regimens were 48 Gy in 4 fractions and 54-60 Gy in 3 fractions. With a median follow up of 22.7 months, there were 17 local failures for a crude relapse rate of 5.7%. Local failure did not differ in patients treated with 3DCRT and IMRT (4.9% vs 6.5%, p=0.573). Mean dose to gross tumor volume (GTV) as a percent of prescription dose was higher with 3DCRT compared with IMRT (107.7% vs 103.6%, p < 0.0001). Tumor stage, histology, and SBRT regimen did not correlate with local tumor control. Overall survival for the entire population approximated 72% at 2 years. Treatment was well tolerated with 6 documented grade 3+ events.

conclusionIn this single-institution cohort of SBRT for early-stage NSCLC, there was no discernible difference in clinical outcomes between those treated with 3DCRT and IMRT.

Indexed as

IMRTradiotherapySABRSBRTstereotactic ablative radiation therapy

Identifiers

PMID31908556
PMCPMC6929968
OpenAlexW2996731765

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.